BioMarin Pharmaceuticals BMRN Total debt
Total debt at other companies
Other financials
Where this comes from
Calculated from BioMarin Pharmaceuticals’s reported figures.
The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioMarin Pharmaceuticals's total debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioMarin Pharmaceuticals's total debt?
- BioMarin Pharmaceuticals (BMRN) reported total debt of $1.43B in Q1 2026.
- How has BioMarin Pharmaceuticals's total debt changed year-over-year?
- BioMarin Pharmaceuticals's total debt increased by 138.4% year-over-year, from $600M to $1.43B.
- What is the long-term trend for BioMarin Pharmaceuticals's total debt?
- Over 5 years (2020 to 2025), BioMarin Pharmaceuticals's total debt has grown at a 62.8% compound annual growth rate (CAGR), from $56.24M to $642.87M.
- What does total debt mean?
- The total amount of money a company owes to lenders and creditors through loans, bonds, and lease obligations.
- How do you interpret total debt?
- An increase in total debt suggests higher financial leverage and increased interest expense, which may heighten financial risk, while a decrease indicates deleveraging and potentially improved balance sheet health.
- How does total debt compare across companies?
- Biotechnology firms often maintain varying levels of debt depending on their stage of commercialization; early-stage companies may carry minimal debt, while mature companies with established product portfolios like BioMarin use debt to manage capital structure and fund R&D or acquisitions.